When was Neurona Therapeutics founded?

Neurona Therapeutics was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Neurona Therapeutics located?

Neurona Therapeutics is headquartered in San Francisco, United States. It is registered at South San Francisco, California.

Who is the current CEO of Neurona Therapeutics?

Cory Nicholas of Neurona Therapeutics.

How many employees does Neurona Therapeutics have?

As of Mar 31, 2026, the latest employee count at Neurona Therapeutics is 104.

Is Neurona Therapeutics a funded company?

Neurona Therapeutics is a funded company, having raised a total of $418M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 21, 2008.

How much is Neurona Therapeutics worth?

The last known valuation of Neurona Therapeutics was $***** as of Apr 03, 2025.

When was the latest funding round of Neurona Therapeutics?

Neurona Therapeutics' latest funding was a $***** Series E round on Mar 28, 2025, with participation from 5 investors.

Where does Neurona Therapeutics rank among its competitors?

Neurona Therapeutics ranks 196th amongst 2850 active competitors, of which 982 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Neurona Therapeutics, which secured $102M in Mar, 2025.

Who are the top competitors of Neurona Therapeutics?

Neurona Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Neurona Therapeutics secured the most recent funding round in March, 2025.

Neurona Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Q: Is Neurona Therapeutics an acquired company?

Neurona Therapeutics got acquired by UCB on Apr 21, 2026.

Neurona Therapeutics is an acquired company based in San Francisco (United States), founded in 2008. It operates as a Developer of cell-based therapies to treat intractable neurological diseases. Neurona Therapeutics has raised $418M in funding from investors like Viking Global Investors, The Column Group and Cormorant Asset Management, with last known valuation of $*****. The company has 2850 active competitors, including 982 funded and 714 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.

Company Details

Developer of cell-based therapies to treat intractable neurological diseases. It generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. It offers NRTX-1001, an inhibitory neuron therapy for epilepsy by GABAergic inhibition, reduce seizure activity, and repair the affected neural network.

Website: www.neuronatherapeutics.com/
Registered Address: South San Francisco, California

Key Metrics

Founded Year

2008

Location

San Francisco, United States

Stage

Acquired

Total Funding

$418M in 9 rounds

Latest Funding Round

Series E, Mar 28, 2025, $*****

Last Known Valuation

$***** as on Apr 03, 2025

Investors

Viking Global Investors & 16 more

Ranked

196^th among 2850 active competitors

Employee Count

104 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 611 more

Exit Details

Acquired by UCB (Apr 21, 2026)

View Neurona Therapeutics' full profile

Neurona Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neurona Therapeutics, Inc. CIN: 262388011 , United States, Active	Dec 31, 2007	-	79 (As on Dec 31, 2024)	-

Neurona Therapeutics got acquired by UCB on Apr 21, 2026 at an acquisition amount of $650M. It was facilitated by Bank of America, Covington & Burling, Centerview Partners and 1 more.

Click here to take a look at Neurona Therapeutics's acquisition in detail

Neurona Therapeutics has raised a total funding of $418M over 9 rounds. Its first funding round was on Aug 21, 2008. Its latest funding round was a Series E round on Mar 28, 2025 for $*****. 5 investors participated in its latest round. Neurona Therapeutics has 17 institutional investors.

Here is the list of recent funding rounds of Neurona Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 28, 2025	4835217	Series E	2830380	9184561	7833060	2692185
Feb 06, 2024	2255250	Series E	5620201	1073312	5166051	The Column Group & 9 more
Dec 22, 2022	8087100	Series D	9943652	8121637	3764009	1851512

Access funding benchmarks and valuations. Sign up today!

View details of Neurona Therapeutics's funding rounds and investors

Neurona Therapeutics' employee count trend

Neurona Therapeutics has 104 employees as of Mar 26. Here is Neurona Therapeutics's employee count trend over the years:

Employee count trend for Neurona Therapeutics

Uncover Neurona Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neurona Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Neurona Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
9th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	GIC, Hudson Bay Capital & 19 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
196th	Neurona Therapeutics 2008, San Francisco (United States), Acquired	Developer of cell-based therapies to treat intractable neurological diseases	$418M	Fidelity Investments, Topspin Fund & 15 others	61/100